Inventaire - your friends and communities are your best library

Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

author

Yoshiyuki Suehara

Anita S Bowman

Ahmet Zehir

Emily K Slotkin

Paul Meyers

Denise Frosina

published in: Clinical Cancer Research

date of publication: 2019-06-07

Cites articles 86

Date

Title

Authors

2019-04-23

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Robert G. Maki
2019-04-15

Detecting the mutational signature of homologous recombination deficiency in clinical samples

June-Koo Lee, Giorgio Melloni, Isidro Cortés-Ciriano, Peter J Park
2018-11-23

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Olivier Mir, Elsa Kalbacher
2018-09-28

Genome-Informed Targeted Therapy for Osteosarcoma

Aviv Spillinger, Soo-Jin Cho, Mi-Ok Kim, Douglas S Hawkins
2018-09-12

Pazopanib in relapsed osteosarcoma patients: report on 15 cases

Alessandra Longhi, Emanuela Palmerini, Marilena Cesari
2018-07-13

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

Emmy Fleuren, Tim R Fenton, Alex von Kriegsheim, Javier Rodríguez, Janet Shipley, Colm J. Ryan, Stephen J Pettitt, Christopher J Lord, Richard Elliott, James Campbell
2017-05-16

OncoKB: A Precision Oncology Knowledge Base

Maeve Lowery
2017-05-08

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Alexander N Shoushtari, Bernard H Bochner, Ahmet Zehir, Ronak H Shah, Sumit Middha, Hyunjae (Ryan) Kim, Jianjiong Gao, Jaclyn F Hechtman, Anoop Balakrishnan Rema, Jacklyn Casanova, Angelica Ochoa, Stacy B Thomas, Dalicia N Reales, Darren R Feldman, Gopa Iyer, Maeve Lowery, Pedram Razavi, David S Klimstra
2016-12-24

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.

Marc Ladanyi, Britta Weigelt
2016-10-09

Advances in sarcoma diagnostics and treatment
2016-06-09

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Robin L Jones, Bartosz Chmielowski
2016-05-26

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

David Jamieson, Alan V. Boddy, Nicola Curtin
2016-03-18

MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research

Andrew S Brohl, Rajesh Patidar, Sivasish Sindiri, Kathleen A Calzone, Toby Trahair, Markku Miettinen
2016-02-15

Profiling of potential driver mutations in sarcomas by targeted next generation sequencing
2016-01-28

Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors

Amy L McGuire, Andrew H. Jea, Donna Muzny, Christine M. Eng, Sarah Scollon, Katie Bergstrom, Robin A Kerstein, Murali Chintagumpala, Stacey L Berg, Sharon E Plon
2016-05-01

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Andrew L Hong, Charles W Roberts
2016-01-27

Corrigendum: Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis

Sabina Signoretti
2016-04

Targeting CDK4 and CDK6: From Discovery to Therapy
2015-11-01

VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
2015

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Brian Schwartz
2015-09-01

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth

John R. Prensner, Andrew C. Harris, Irfan Asangani, Nallasivam Palanisamy, Arul Chinnaiyan, Martin R. Delany, Xuhong Cao, Robert J Lonigro, Sameek Roychowdhury, Pankaj Vats
2015-06-12

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

Shaomeng Wang
2015-03-20

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

Marc Ladanyi, Jacklyn Casanova, Jinjuan Yao, Jaclyn F Hechtman, Ronak H Shah
2015-04-01

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome

Sebastian Ribi, Babita Madan, Shaojiang Cai, Jan Smida, David M. Virshup
2014-12-24

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Elisa de Stanchina
2014-12-15

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Carrie Sougnez, Gad Getz, Amaro Taylor-Weiner, Chandra Sekhar Pedamallu, Eric Lander, Jaume Mora, Stacey Gabriel, Levi A Garraway, Todd Golub, Andrey Sivachenko, Loren D. Walensky, Charles W Roberts, Glenn S Cowley, Cinzia Lavarino, Aaron McKenna
2014-11-14

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel

Rebecca Ellston
2014-10-16

Translational biology of osteosarcoma

Mark J. Smyth, David M Thomas
2014-08-21

Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients

Akmal Safwat, Philip Rossen
2014-04-03

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma

Xiang Chen, Elaine Mardis, James T Dalton, Matthew Parker
2014-03-31

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment

Luigi Tornillo, Naama Kanarek, Luca Quagliata, Kai Breuhahn
2014-02-12

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

Josep Baselga, Reinhard Dummer

Article - wd:Q92594621

Welcome to Inventaire

the library of your friends and communities

learn more